
PET-Guided Strategy May Spare Chemotherapy in HER2-Positive Breast Cancer
Key Takeaways
- PHERGain tested 18F-FDG-PET after two cycles to adapt therapy, continuing dual HER2 blockade without chemotherapy for metabolic responders and escalating to chemotherapy for nonresponders and non-pCR cases.
- Five-year iDFS was 89.5% in the PET-guided surgical cohort versus 96.7% with standard TCHP, without formal comparative intent given the noncomparative phase 2 design.
Five-year PHERGain results support PET-guided treatment de-escalation in HER2-positive breast cancer, with ctDNA offering insight into recurrence risk
A positron emission tomography (PET)-guided, response-adapted treatment strategy was associated with favorable 5-year invasive disease-free survival (iDFS) in patients with HER2-positive early breast cancer, potentially allowing selected patients to avoid chemotherapy, according to findings from the phase 2 PHERGain trial (NCT03161353) published in Nature Medicine.¹
At a median follow-up of 5.6 years, the 5-year iDFS rate was 89.5% (95% CI, 85.7%-93.4%) among patients assigned to the PET-guided treatment strategy. Among the 86 patients who achieved a PET response and pathological complete response (pCR) without chemotherapy, the 5-year iDFS rate was 92.4% (95% CI, 86.7%-98.5%), with 1 distant recurrence.
The findings provide longer-term evidence supporting individualized
PET Imaging Guided Chemotherapy De-Escalation
PHERGain was a randomized, open-label, noncomparative phase 2 trial evaluating whether PET imaging and pathological response could guide chemotherapy de-escalation in patients with HER2-positive, operable stage I to IIIA breast cancer with tumors measuring at least 1.5 cm.¹
Patients were randomly assigned to a standard-treatment arm (group A), which received neoadjuvant docetaxel and carboplatin plus trastuzumab (Herceptin) and pertuzumab (Perjeta), or a PET-guided treatment arm (group B), which initially received trastuzumab and pertuzumab without chemotherapy, with endocrine therapy for patients with hormone receptor-positive disease. Treatment in group B was subsequently adapted according to PET response and pathological findings.¹˒²
After 2 treatment cycles, patients in group B underwent PET imaging. Those demonstrating a metabolic response, defined as at least a 40% reduction in maximum standardized uptake value, continued HER2-targeted treatment without chemotherapy. Patients without a PET response transitioned to chemotherapy. Additionally, patients who demonstrated a PET response but did not achieve pCR at surgery received chemotherapy.
Among patients in group B who underwent surgery according to protocol (n = 267), the 5-year iDFS rate was 89.5% (95% CI, 85.7%-93.4%). The corresponding rate in the group A surgical population (n = 63) was 96.7% (95% CI, 92.2%-100%). The study was not designed for formal comparisons between treatment groups.¹
Importantly, the 92.4% iDFS estimate among patients who achieved pCR without chemotherapy describes a subgroup defined after randomization. The investigators emphasized that this result should be interpreted descriptively rather than as evidence of a causal benefit from chemotherapy omission.
ctDNA Clearance Was Linked to Improved Outcomes
Investigators also evaluated ctDNA as a potential biomarker of
Early ctDNA clearance was associated with a higher pCR rate than persistent detection (48.4% vs 22.0%; P = .003). Additionally, none of the 28 patients with detectable ctDNA before surgery achieved pCR.
Baseline ctDNA positivity was associated with lower 5-year iDFS than undetectable ctDNA (86.7% vs 97.1%; HR, 3.10; 95% CI, 1.0-9.8; P = .021). Early ctDNA clearance was also associated with improved 5-year iDFS compared with persistent detection (92.3% vs 75.6%; HR, 2.90; 95% CI, 1.1-7.3; P = .028). However, this association did not retain statistical significance after adjustment for disease stage and nodal status.
The investigators noted that ctDNA analyses were exploratory and that further prospective validation is needed before the biomarker can guide treatment decisions in clinical practice.
Findings Support Further Treatment Individualization
The investigators acknowledged several limitations, including the noncomparative phase 2 design, relatively small sample size, and potential attrition bias associated with extended follow-up. Additionally, the subgroup of patients who achieved pCR without chemotherapy was defined after randomization, limiting conclusions about the causal effects of chemotherapy omission.
The study also predates the incorporation of adjuvant trastuzumab emtansine (T-DM1; Kadcyla) for patients with residual invasive disease following neoadjuvant treatment, which has since become an important component of HER2-positive early breast cancer management.
The investigators concluded, “These findings continue to support the clinical validity of an ¹⁸F-FDG-PET-guided, pCR-adapted approach and suggest a potential role for ctDNA in refining treatment individualization.”¹
REFERENCES
1. Pérez-García JM, Cortés J, Ruiz-Borrego M, et al. 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial. Nat Med. Published online October 29, 2026. doi:10.1038/s41591-026-04723-w
2. Pérez-García JM, Cortés J, Ruiz-Borrego M, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024;403(10437):1649-1659. doi:10.1016/S0140-6736(24)00054-0
Related to this article








